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Abstract
Background: People who inject drugs (PWID) are at increased risk of acquiring and transmitting HIV
and Hepatitis C (HCV) due to sharing injection paraphernalia and unprotected sex. To generate
seroprevalence data on HIV and HCV among PWID and related data on risk behaviour, a multicentre
sero- and behavioural survey using respondent driven sampling (RDS) was conducted in eight German
cities between 2011 and 2014. We also evaluated the feasibility and effectiveness of RDS for recruiting
PWID in the study cities.
Methods: Eligible for participation were people who had injected drugs within the last 12 months,
were 16 years or older, and who consumed in one of the study cities. Participants were recruited, using
low-threshold drop-in facilities as study sites. Initial seeds were selected to represent various sub-groups
of people who inject drugs (PWID). Participants completed a face-to-face interview with a structured
questionnaire about socio-demographics, sexual and injecting risk behaviours, as well as the utilisation of
health services. Capillary blood samples were collected as dried blood spots and were anonymously tested
for serological and molecular markers of HIV and HCV. The results are shown as range of proportions (min.
and max. values (%)) in the respective study cities. For evaluation of the sampling method we applied criteria
from the STROBE guidelines.
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Results: Overall, 2,077 PWID were recruited. The range of age medians was 29–41 years, 18.5–35.3 % of
participants were female, and 9.2–30.6 % were foreign born. Median time span since first injection were
10–18 years. Injecting during the last 30 days was reported by 76.0–88.4 % of participants. Sharing needle/
syringes (last 30 days) ranged between 4.7 and 22.3 %, while sharing unsterile paraphernalia (spoon,
filter, water, last 30 days) was reported by 33.0–43.8 %. A majority of participants (72.8–85.8 %) reported
incarceration at least once, and 17.8–39.8 % had injected while incarcerated. Between 30.8 and 66.2 % were
currently in opioid substitution therapy. Unweighted HIV seroprevalence ranged from 0–9.1 %, HCV from
42.3–75.0 %, and HCV-RNA from 23.1–54.0 %. The implementation of RDS as a recruiting method in
cooperation with low-threshold drop in facilities was well accepted by both staff and PWID. We reached
our targeted sample size in seven of eight cities.
Conclusions: In the recruited sample of mostly current injectors with a long duration of injecting drug
use, seroprevalence for HIV and HCV varied greatly between the city samples. HCV was endemic among
participants in all city samples. Our results demonstrate the necessity of intensified prevention strategies for
blood-borne infections among PWID in Germany.
Keywords: PWID, Sero- and behavioural survey, HIV, Hepatitis C, Respondent-driven sampling, Second
generation surveillance, Injecting drug users, Germany, Europe
Abbreviations: CI, Confidence intervals; DRUCK-study, Drugs and chronic infectious diseases study (Studie
zu “Drogen und chronischen Infektionskrankheiten”); ECDC, European centre of disease prevention and
control; HCV, Hepatitis C virus; HCV RNA, Hepatitis C virus ribonucleic acid; HIV, Human immunodeficiency
virus; IDU, Injecting drug users; NSP, Needle and syringe exchange programme; n/s, Needles and syringes;
OST, Opioid substitution treatment; PWID, People who inject drugs; RKI, Robert Koch-Institute;
UNODC, United Nations Office on Drugs and Crime; RDS, Respondent-driven sampling; VCT, Voluntary
testing and counselling
Background
According to estimations 15 million people were living
with the hepatitis C virus (HCV) in the WHO European
Region in 2013 [1], and 2.2 million with the human
immunodeficiency virus (HIV) [2]. In most European
countries people who inject drugs (PWID) are a key
transmission group for blood-borne infections, including
HCV and HIV [3, 4]. Studies identified several risk fac-
tors to be associated with HCV [5–11] and HIV [12, 13]
infections among PWID including years of injecting,
sharing of needles, syringes and other equipment, im-
prisonment and unprotected sex.
HIV and HCV testing are common interventions for
HIV and HCV surveillance and control. They increase
knowledge of HIV and HCV status, and ought to be
entry points to HIV- and HCV-related treatment and
care. It has been shown that opioid substitution therapy
(OST) reduces injecting drug use by lowering the
frequency of injecting and related unsafe practices,
thereby effectively decreasing the transmission of HIV
[14–16] and in combination with needle and syringes
programmes (NSP) also of HCV [17]. It furthermore
facilitates regular medical care and adherence to HIV
and HCV treatment [18–20].
Knowledge about HIV and HCV prevalence and re-
lated behaviour amongst PWID in Germany is currently
based on outdated regional studies of convenience
samples. Studies providing a clear and up-to-date picture
of the epidemiology of HCV and HIV amongst PWID in
Germany do not exist and ongoing monitoring of infec-
tions or risk behaviours among PWID is not established.
Nevertheless, regional surveys from the last decades in
Germany have indicated that HCV is hyperendemic in
PWID [21–24]. While the prevalence of HCV infection
in the most recent population-based survey in the adult
population was 0.3 %, local surveys among PWID have
found prevalence ranging from 50–80 % [22–25]. High
rates of infection in the PWID population were also
reported from other European countries with anti-HCV
prevalence ranging from 13.8 to over 90 % [26]. National
estimates in Germany show that PWID are also at-risk
of HIV transmission. Nearly 10 % of all estimated HIV
infections were attributed to injecting drug use as of end
of 2014 [27]. According to Backmund, in 2007 HIV
prevalence among PWID in Germany must have been
between 4.3 and 6.5 % [28] and thus, significantly higher
than in the general population, where HIV infections are
below 0.1 % [29]. Although there are variations across
Western European countries, prevalence above 5 %
among PWID has been reported in France, Spain,
Ireland, Greece, Portugal, and Sweden in recent years
[26]. Due to preventive efforts the number of newly
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diagnosed HIV infections among PWID in Germany has
been declining since a peak in the late 1980ies. In 2014,
an estimated 7.5 % of the 3,200 new HIV cases (240)
were caused by transmission among PWID, including a
sizeable proportion of approximately 25–30 % of these
infections being diagnosed in Germany, but being origin-
ally acquired in Eastern or Central Europe [27]. Chronic
co-infection with HCV and HIV is also common among
PWID in some European countries, with a high preva-
lence of co-infection ranging between 15 and 70 %
reported by Estonia, France, Latvia, Italy, Netherlands,
Poland, Portugal and Spain [30].
To tackle the risk of blood-borne and sexually trans-
mitted infections among PWID it is essential to combine
behavioural, socio-demographic and serological data to
inform the planning and implementation of effective
prevention and intervention strategies [31]. By iden-
tifying knowledge gaps regarding the transmission and
prevention of infections, and by revealing risky and pre-
ventive practices, factors that drive transmission among
PWID can be identified and addressed. Based on such
information, specific recommendations for reducing risk
behaviours, scaling up prevention, treatment and care
can be formulated. To obtain information on the preva-
lence of blood-borne infections and related behaviours
for PWID in Germany, we conducted a sero-behavioural
study using respondent driven sampling (RDS) in eight
large cities across the country in cooperation with low-
threshold drug services.
Sampling hard-to-reach populations
Standard probability methods are generally difficult to
apply in hard-to-reach populations, where a sampling
frame for the targeted population is not available. RDS
was introduced by Heckathorn in 1997 as a modified
snowball method to recruit hard-to-reach populations
[32]. Globally, more than 460 studies from 69 countries
applying RDS have been published, and several studies
have used RDS to recruit PWID in recent years [33].
Due to their strong social networks and because PWID
often buy from and inject drugs with other PWID, RDS
worked well as a recruitment method in the majority of
studies [34, 35]. RDS works effectively as a sampling
method, when four requirements are met [32]: first, par-
ticipants need to know one another through the network
of the group under study. Second, the network needs to
be dense enough to attain a sample with sufficient socio-
metric depth in order to reach equilibrium. The statis-
tical rationale of RDS depends on the stabilization of the
sample composition after a sufficient number of rec-
ruitment waves - the point at which the characteristic
proportions remain stable, even if the recruitment con-
tinues is known, as the equilibrium [32]. The number of
waves required to reach equilibrium is again linked to
the third requirement: random recruitment must set in
at some point to avoid that sampling is limited to a
specific sub-group and only reflecting the characteristics
of the seed with which the chain began. The tendency to
recruit persons who are similar and thereby causing bias
in the samples is termed homophily. Fourth, an enabling
system to motivate participants to recruit other partici-
pants must be in place [36].
Objectives
In this paper we present descriptive results of the first
sero-behavioural study of PWID using RDS performed in
Germany. The objectives are to describe basic characteris-
tics of participants in the respective study cities focusing
on i) socio-demographic factors, ii) seroprevalence of HIV
and HCV, including co-infections, iii) use of health
services, and iv) injecting and sexual risk behaviours.
Furthermore, we assess whether RDS was effective for
sampling PWID in the study cities.
Methods
Detailed information about methodological issues has
been described earlier [37].
Overview
From 2011 to 2014, we recruited PWID using RDS
across eight cities in Germany targeting a sample of
200–400 PWID in each city. All cities have a relatively
large PWID community and were selected for their
geographic and demographic diversity as well as the
availability of low-threshold drop-in facility services.
Four of the cities - Berlin, Cologne, Munich and Hamburg
- have more than one million inhabitants; the four others
- Essen, Leipzig, Frankfurt on the Main (Frankfurt) and
Hanover- between 500,000 and 700,000.
Study population
Eligibility for participation was defined as i) aged 16 or
older, ii) self-reported injecting drug use within the past
12 months in the respective city, iii) willingness to take
part in an questionnaire assisted-interview and to pro-
vide a capillary blood specimen for serological and mo-
lecular testing iv) willingness to give informed consent,
and v) not having participated in the study previously.
Sampling method
Sampling started with a small number of initial recruits
(‘seeds’) in each city, selected by local partners of low
threshold drug services to represent a range of charac-
teristics (gender, country of birth, residential area and
preferred low-threshold drug service, self-reported HIV
serostatus, mainly preferred substance, former experi-
ence of sex work and imprisonment). All seeds were
selected based on an anonymous list of PWID and their
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characteristics provided by the local partners. The
recruitment expanded through so called ‘recruitment
waves’ of peers; after the seeds recruited the first recruit-
ment wave of participants the first recruitment wave
continued to recruit the second recruitment wave of
participants and so on until the targeted sample size
was reached.
Recruitment process
In each city we established between one and four RDS
study sites in local low-thresholds drop-in facilities,
where participants enrolled in the survey and redeemed
their coupons. The recruitment coupons were valid for
two weeks. Each individual received 10 EUR for partici-
pating in the study, and was paid an additional 5 EUR
for each eligible drug user they recruited. To ensure
anonymity and to track the recruitment process we
assigned a unique numeric identifier to each participant.
If a seed turned out not to be productive additional
seeds were selected if needed to keep the recruitment
process ongoing. Recruitment and data collection was
conducted by staff of low-threshold drug services who
are trained to work with PWID. This recruitment
process continued until the end of the scheduled recruit-
ment period which was reached after 7 to 9 weeks.
Demographic, behavioural and serological data and
network information
Staff of the Robert Koch Institute (RKI) conducted a
two-day pre-survey training on study design, RDS
methodology, standardised interviews, blood sample
collection procedures and logistics for the staff of low-
threshold drug services in the respective study cities.
Eligible PWID had to undergo a questionnaire-assisted
interview in German or Russian, wherever Russian-
speaking staff was available. We asked questions reg-
arding respondent’s demographic characteristics, their
knowledge, attitudes, behaviour and practices as well as
their network. Minor modifications were made in the
questionnaire throughout the four years while conduct-
ing the survey. Therefore, some variables are not avail-
able for all cities. The network size was determined by
asking respondents how many PWID (fulfilling the
inclusion criteria for the study) they know by name who
would also know the respondent by name. We also
asked how many of these persons they believed they
could recruit for the study. The questionnaire was based
on a model questionnaire developed by the European
Monitoring Centre for Drugs and Drug Addiction
(EMCDDA), and additional indicators proposed by the
European Centre of Disease Control (ECDC) and the
Global AIDS response progress reporting (GARPR)
[38–40]. Dried blood spots (DBS) on filter cards
(Whatman #903) were obtained from participants’ capillary
blood.. During the pilot phase of the study (cities of Essen
and Berlin), DBS testing was validated in the Institute of
Virology, National Reference Centre (NRZ) for Hepatitis C,
at the University of Duisburg-Essen, which subsequently
also performed the regular analyses on serological and
molecular markers of HIV and HCV. The Division for
HIV and other Retroviruses and the Division for Viral
Gastroenteritis and Hepatitis Pathogens and Enterovi-
ruses in the Department for Infectious Diseases at the
RKI were in charge of the laboratory testing for the
remaining six cities. The study flow and laboratory pro-
cedures including possible shortcomings arising from
DBS testing are described in detail elsewhere [37, 41].
Prevalence of infection was determined by detection of
anti HIV or anti HCV antibodies and detection of
molecular markers for HIV and HCV by nucleic acid
amplification tests. Pre- and post-test counselling were
offered to participants according to international and
national recommendations [42].
Measures to assess the effectiveness of RDS
For evaluation of the sampling method we applied cri-
teria following the guidelines for “Strengthening the
Reporting of Observational Studies in Epidemiology for
RDS Studies” (STROBE-RDS), a checklist of essential
items to present in RDS publications [33]. We provide
information about the relationship of respondents with
their recruiters and calculated the equilibrium and the
number of recruitment waves for five key variables: I.
participants’ mean age; II. proportion of male partici-
pants; III. proportion of PWID born in Germany; IV.
HCV prevalence; and V. HIV prevalence. Furthermore,
we describe the level of homophily among the study
population. Homophily (Hx) was analysed for the follow-
ing three outcomes: age, gender and HIV serology. As
recommended a graphical representation of the entire
recruitment network for all study cities is included.
Finally, we assess whether the incentives could motivate
PWID to participate in the study. Detailed material of
this evaluation is attached in the Additional file.
Statistical analysis
For data entry we used EpiData 3.0. We applied des-
criptive statistics by using Stata version 14.0. The crude
sample proportions are presented for all cities in
Tables 1, 2 and 3. The results are shown as range of
proportions (min. and max. values (%)) for the respective
study cities. Based on the reported network size of each
participant, we used the respondent driven sampling
analysis tool RDSAT version 7.1 (http://www.resp-
ondentdrivensampling.org) to define population pro-
portions and variance estimates of each dataset [43]. We
included seeds in the analysis. The number of re-
samplings to determine bootstrap 95 % confidence
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intervals (CI) was set to 15,000 to improve the accuracy
of the variance estimates and the network size outliers
pulled in by 5 %. The enhanced smoothing algorithm
type was employed as recommended by Johnston [44].
The RDS estimated population proportions based on the
reported network are provided in the (Additional file 1:
Table S1). We used RDSAT 7.1 to calculate homophily
for all eight data sets. The homophily (Hx) metric is be-
tween −1 und 1. In line with Heckathorn’s suggestion we
defined any value of Hx ≥ 0.3 as intermediate homophily
and any value ≤ −0.3 as strong heterophily [45]. We ap-
plied Stata 14.0 to calculate equilibrium and the number
of recruitment waves. Equilibrium was attained when
the sample distribution from one recruitment wave to
the next fell within a discrepancy of less than 2 % [46].
Results
Socio-demographic characteristics of participants
Overall, we recruited a total of 2,079 participants in the
multicentre survey, of which two did not meet our
eligibility criteria. Most of the interviews took around
45 min to 1 h to complete. In each city except Leipzig
(n = 130) a sample size between 200–400 PWID was
achieved (see Table 4). In all cities the proportion of
female participants ranged between 18.5 and 35.3 %.
The median age of participants varied between 35–41
years – except in Leipzig where the median age was
29 years. Accordingly, the proportion of PWID younger
than 25 years was higher in Leipzig (26.9 %) compared
to the remaining seven cities (2.1–9.0 %). Leipzig was
also an exception with regards to country of origin of
the participants. Foreign-born participants accounted for
9.2 % in Leipzig and ranged between 16.6 and 30.6 % in
the other seven cities. The proportion of participants
born in Eastern Europe and Former Soviet Union ranged
between 6.3 in Leipzig and 24.7 % in Berlin.
The majority of participants in all cities had completed
lower secondary school (40.4–58.3 %) and between 8.5
and 20.8 % had not completed any school. Between
72.3–90.4 % reported currently receiving social benefits/
Table 1 Socio-demographic variables, 2011-14a
Berlin Essen Leipzig Frankfurt Cologne Hanover Munich Hamburg range
n = 337 n = 197 n = 130 n = 285 n = 322 n = 252 n = 235 n = 319 (min-max)
n % n % n % n % n % n % n % n % %



















<25 years 30 9.0 9 4.6 35 26.9 6 2.1 11 3.4 15 6.0 16 6.8 13 4.1 2.1-26.9
Gender Female 62 18.5 39 19.8 29 22.3 73 25.8 73 22.7 50 19.8 83 35.3 71 22.3 18.5-35.3




83 24.7 20 10.2 8 6.3 34 11.9 22 6.8 40 15.9 23 9.8 62 19.5 6.3-24.7
Educational level No school
certificate




143 42.4 109 55.6 62 48.1 147 52.1 130 40.4 119 47.2 137 58.3 135 42.6 40.4-58.3
Completed
10th grade
121 35.9 38 19.4 45 34.9 78 27.7 74 23.0 78 31.0 52 22.1 95 30.0 19.4-35.9
High school
graduate







56 16.8 29 14.7 25 19.4 67 23.8 59 18.3 61 24.2 67 28.6 84 26.8 14.7-28.6
Social benefits/
pension
289 86.5 176 89.3 111 86.1 231 81.9 291 90.4 217 86.1 192 82.1 229 72.9 72.9-90.4
Homelessness In the last
12 monthsc
29 8.6 28 14.2 28 21.5 79 28.7 48 15.3 17 6.8 27 11.5 55 17.3 6.8-28.7
Ever 216 64.5 128 65.0 100 76.9 210 73.9 218 68.1 133 52.8 139 59.2 225 70.8 52.8-76.9
aFootnote (Table 1): Because not all participants replied to every variable, some variables include missing values. This means that the city-specific denominator for
some variables might be lower than the n displayed at the top of the table
bEastern Europe and Former Soviet Union: Includes PWID reporting being born in the following 24 countries: Azerbaijan, Bosnia & Herzegovina, Bulgaria, Croatia,
Czech Republic, Estonia, Georgia, Hungary, Kazakhstan, Kosovo, Kyrgyzstan, Latvia, Lithuania, Montenegro, Poland, Romania, Russian Federation, Serbia, Slovakia,
Slovenia, Tajikistan, Ukraine, Uzbekistan and Yugoslavia
cMain reported form of residence, includes living on the street and in homeless shelters
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pensions. Furthermore, more than half of the partici-
pants in all cities had been homeless at least once in life
(52.8–76.9 %). Between 6.8 (in Hanover) and 28.7 % (in
Frankfurt) of the participants reported being homeless
or staying in homeless shelters as their main residence
in the past 12 months (Table 1).
Seroprevalence of HIV and HCV and use of health care
services
HIV prevalence amongst participants varied between
0 % in Leipzig and 9.1 % in Frankfurt. HCV prevalence
(Anti-HCV or HCV-RNA positive or both) ranged from
42.3 in Leipzig to 75.0 % in Hanover (Fig. 1), while HCV
viremic infections (HCV-RNA positive) were found to
range from 23.1 in Leipzig to 54.0 % in Hanover. HCV-
RNA in the absence of anti-HCV antibodies was
detected in 0.9 % of the cases in Munich and in 5.4 % of
the cases in Leipzig, indicating recent HCV infections
before seroconversion. HCV co-infections amongst the
HIV positive participants were detected between 60.0 %
of cases in Cologne and 100 % in Essen.
Use of health services and testing history
Data on utilisation of low-threshold drug services (in the
last 30 days) was collected in five of the eight study
cities. The proportion of PWID who visited a low-
threshold drug service in the last 30 days ranged from
78.7 to 90.5 %. About three out of five participants in
each of the eight cities (54.6–88.9 %) reported ever
receiving opioid substitution therapy (OST). Currently
receiving OST varied between 30.8 in Leipzig and 66.2 %
in Cologne. In all cities the vast majority had been tested
for HIV during their lifetime (76.6–97.5 %). Undergoing
an HIV test in the last 12 month was reported by 43.9 %
(Leipzig) to 69.9 % (Munich). The majority of the study
population in each city reported ever being tested for
HCV antibodies (70.3–96.0 %), while having been tested
recently (12-month prevalence) was reported between
28.8 (Leipzig) and 75.4 % (Munich) (Table 2).
Recent substance use and risk behaviours
The median number of years since first injection was
10 years in Leipzig, 13 years in Berlin and between 16
and 18 years in the remaining cities. In seven cities, the
proportion of participants who initiated injecting in the
last two years ranged from 3.2 in Hanover to 7.8 % in
Berlin. In Leipzig one out of ten (11.1 %) had started
injecting in the last two years.
Injecting drugs in the last 30 days was reported by
more than three out of four participants in all eight
cities (76.0–88.4 %) and daily injection in the last 30 days
varied between 17.2 in Munich and 39.1 % in Berlin. In
the last 30 days Heroin was the most frequently used
substance (all routes of administration) in five cities
Table 2 Serological and molecular findings for HIV and HCV and use of health care services, 2011-14a
Berlin Essen Leipzig Frankfurt Cologne Hanover Munich Hamburg range
n = 337 n = 197 n = 130 n = 285 n = 322 n = 252 n = 235 n = 319 (min-max)
Serological and molecular findings n % n % n % n % n % n % n % n % %
HIV + 13 3.9 12 6.1 0 0 26 9.1 5 1.6 22 8.7 7 3.0 16 5.0 0.0-9.1
HCV seroprevalence; Anti-HCV
+ and/or HCV-RNA +
185 54.9 143 72.6 55 42.3 189 66.3 229 71.1 189 75.0 149 63.4 222 69.6 42.3-75.0
Cleared infection; Anti HCV+, HCV RNA - 60 17.8 54 27.4 25 19.2 46 16.1 76 23.6 53 21.0 64 27.2 79 24.8 16.1-27.2
Chronic infection; Anti HCV+, HCV RNA + 125 37.1 89 45.2 30 23.1 143 50.2 153 47.5 136 54.0 85 36.2 143 44.8 23.1-54.0
Seroconverters; Anti HCV-, HCV RNA + 4 1.2 3 1.5 7 5.4 5 1.8 15 4.7 5 2.0 2 0.9 6 1.9 0.9-5.4
Co-infections: Anti HIV+, Anti HCV
+ and/or HCV RNA+
12 92.3 12 100.0 - - 21 80.8 3 60.0 19 86.4 6 85.7 11 68.8 60.0-100.0
Use of health care services and testing history
Use of harm reduction service (last 30d) b - b - b - 256 90.5 261 81.3 221 87.7 185 78.7 284 89.0 78.7-90.5
Currently in OST 135 40.3 85 43.2 40 30.8 129 45.3 213 66.2 109 43.3 129 55.1 179 56.3 30.8-66.2
Ever receiving OST 244 72.8 170 86.3 71 54.6 233 81.8 279 86.7 211 83.7 208 88.9 254 79.6 54.6-88.9
Ever tested for HIV 298 90.6 184 94.4 98 76.6 277 97.5 302 95.0 233 94.3 220 96.1 301 95.0 76.6-97.5
Tested for HIV (last 12 m)c 173 57.1 125 68.3 54 43.9 171 66.3 207 69.7 137 60.6 146 69.9 197 68.4 43.9-69.9
Ever tested for HCV 287 89.4 184 94.9 85 70.3 264 94.6 290 93.6 224 91.8 215 96.0 269 90.0 70.3-96.0
Tested for HCV (last 12 m)d 70 49.0 39 59.1 21 28.8 44 54.3 60 58.8 30 42.3 52 75.4 47 46.5 28.8-75.4
aFootnote (Table 2): Because not all participants replied to every variable, some variables include missing values. This means that the city-specific denominator for
some variables might be lower than the n displayed at the top of the table
bdata not collected
cExcluding those with a diagnosis older than 12 months
dDenominator includes those never tested, those never tested positive and those who had their first HCV diagnosis in the last 12 months
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(Berlin: 83.1 %; Essen: 78.2 %; Cologne: 85.4 %; Hanover:
75.0 % and Munich 56.8 %); while in Leipzig metham-
phetamine was the most frequently reported substance
(67.4 %). In the other seven cities methamphetamine
was less common (0.0–6.4 %). Crack was used by a high
proportion of participants in three cities (Frankfurt:
71.6 %; Hanover: 58.6 % and Hamburg: 45.9 %) while
reported by much lower proportions in the remaining
five cities (0.4–3.1 %). Cocaine use was lower in Berlin
(37.1 %), Leipzig (17.7 %) and Munich (20.9 %)
compared to Frankfurt (44.0 %), Cologne (46.7 %), Essen
(60.9 %), Hanover (65.9 %) and Hamburg (79.9 %).
Sharing of unsterile needles and syringes (n/s) in the
last 30 days was reported by 10.6 % in Hamburg and
up to 22.3 % in Hannover among participants who
reported having injected during the last 30 days.; only
in Frankfurt the proportion was lower (4.7 %). Recent
sharing of unsterile equipment like spoons, filters or
water for injection with other injectors was reported
by 33.0 % in Hanover and Hamburg and by up to
43.8 % in Frankfurt among persons who injected
during the last 30 days.







































Injecting <2 years 26 7.8 10 5.1 14 11.1 14 4.9 13 4.0 8 3.2 12 5.2 19 6.0 3.2-11.1
Injected drugs (last 30d) 279 82.8 170 86.3 99 76.2 238 83.5 263 81.7 202 80.2 187 79.6 282 88.4 76.2-88.4
Injected daily (last 30d) 108 39.1 57 33.7 29 30.2 72 31.2 84 32.3 65 32.2 32 17.2 69 24.7 17.2-39.1
Heroin consumed (last 30d) 280 83.1 154 78.2 89 68.5 224 78.6 275 85.4 189 75.0 133 56.8 201 63.2 56.6-85.4
Cocaine consumed (last 30d) 125 37.1 120 60.9 23 17.7 125 44.0 150 46.7 166 65.9 49 20.9 255 79.9 17.7-79.9
Crack consumed (last 30d) 8 2.4 6 3.1 1 0.8 204 71.6 6 1.9 147 58.6 1 0.4 146 45.9 0.4-71.6












237 72.9 144 77.0 110 84.6 228 80.9 224 74.2 182 73.7 193 82.1 237 75.0 72.9-84.6
No condom use during
last sexual intercourse
130 56.1 59 44.9 45 63.4 125 56.3 138 61.6 109 60.2 130 69.1 134 56.5 44.9-69.1
Last sex partner was IDU 134 57.5 73 51.4 70 68.6 139 65.6 120 56.1 105 64.4 127 69.4 118 54.1 51.4-69.4
Incarceration
Ever incarcerateda 257 76.5 169 85.8 108 83.1 239 84.2 262 81.9 214 85.6 171 72.8 254 79.6 72.8-85.8
Total duration
of incarceration




























81 24.2 67 34.5 39 32.2 79 27.8 97 30.2 76 30.3 45 19.4 71 22.3 19.4-34.5
aIncluding juvenile arrest/prison, pre-trial custody, prison, forensic commitment
bFootnote (for Table 3): Because not all participants replied to every variable, some variables include missing values. This means that the city-specific denominator
for some variables might be lower than the n displayed at the top of the table
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Sexual risk behaviours
Between 72.9 and 84.6 % of participants reported en-
gaging in sexual intercourse in the last 12 months,
of which 44.9 % in Essen and up to 69.1 % in Mun-
ich reported not having used a condom at last sexual
intercourse. More than half of the participants re-
ported that their last sexual partner was also inject-
ing drugs (51.4 % in Essen and up to 69.4 % in
Munich).
History of incarceration
Imprisonment (ever) was reported by the majority
of participants in all cities (72.8–85.8 %) and
median of total duration of incarceration ranged be-
tween 2.0 years in Leipzig, Berlin and Munich to
5.0 years in Hanover. Of those who had ever been
in prison, between 17.8 % in Leipzig and 39.3 % in
Berlin reported injecting drugs while incarcerated.
Of these, between 33.0 and 49.4 % had shared n/s
or other equipment when injecting during their last
incarceration. Tattooing and piercing during impris-
onment were reported by 19.4 % of the participants
in Munich and up to 34.5 % of the participants in
Essen.
The detailed data on substance use and risk behaviours
in the last 30 days are shown in Table 3.
Table 4 Details of the recruitment procedures using RDS in eight German cities, 2011-14
Berlin Essen Leipzig Frankfurt Cologne Hanover Munich Hamburg
(n = 337) (n = 197) (n = 130) (n = 285) (n = 322) (n = 252) (n = 235) (n = 319)
Target sample size 300-350 200 200 300 300 200-250 200 300
Month and year of recruitment 05-07. 2011 10-12. 2011 10-12.2011 01-03.2013 04-05.2013 07-09.2013 10-12.2013 03-05.2014
Time of recruitment 8 weeks 8 weeks 7 weeks 9 weeks 8 weeks 8 weeks 8 weeks 8 weeks
No. of study sites 4 1 2 2 1 1 1 1
No. of seeds in total 19 18 13 11 12 7 13 9
No. of unproductive seeds 4 6 4 2 0 4 3 0
Max. number of recruitment waves 13 10 8 20 13 14 14 20
Coupon received from partner a a 7 % 5 % 2 % 4 % 3 % 2 %
Coupon received from acquaintance a a 78 % 64 % 84 % 50 % 67 % 65 %
Coupon received from stranger a a 15 % 31 % 14 % 46 % 30 % 33 %
adata on the relationship to the recruiter was not collected in first two study cities
Fig. 1 HIV and HCV seroprevalence in the eight cities (%)
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Evaluation of the sampling method: respondent driven
sampling
Between 7 and 19 seeds started the recruitment process
in the respective cities. The sample of Leipzig (n = 130)
reached a maximum of eight recruitment waves, while
the samples of Frankfurt and Hamburg reached a max-
imum of 20 recruitment waves (Table 4). Equilibrium
and homophily were assessed after the recruitment
process had been completed. We reached equilibrium
for four of the following five key variables: I. partici-
pants’ median age; II. proportion of male participants;
III. proportion of PWID born in Germany; IV. HCV
prevalence; and V. HIV prevalence in all study cities
except in Leipzig. Equilibrium for HIV prevalence was
not attained in our sample of Frankfurt, Hanover and
Cologne. The results of these analyses are presented in
the (See Additional file 2: Figure S1a, Additional file 3:
Figure S1b, Additional file 4: Figure S1c, Additional file 5:
Figure S1d, Additional file 6: Figure S1e and Additional
file 7: Figure S2). Respondents and recruiters had the
following relationships: Most participants (54–86 %)
received their coupons from their partner or from an
acquaintance. Between 14 % of the participants in Cologne
and up to 46 % of the participants in Hanover received
their coupons from a stranger (Table 4). The reported
network size defined as “how many people who injected
drugs in the last 12 months do you know (and they know
you)” ranged from 0–1400 individuals. We did observe
random recruitment among the participants. In Frankfurt,
Cologne and Hamburg young participants (<25 years)
demonstrated a strong negative homophily, indicating that
younger participants only recruited older participants (Hx
= −1). Among the female participants, only women in
Leipzig demonstrated a negative homophily (Hx = −0.37).
In Cologne and Munich HIV positive participants only
recruited HIV negative participants (Hx = −1) while HIV
negative participants in Cologne demonstrated intermedi-
ate homophily recruiting mostly other HIV negative
participants (Hx = 0.67). The recruitment chains in Co-
logne and Hamburg show a very late recruitment of HIV
positive PWID in the study sample (See Additional file 8:
Figure S4e and Additional file 9: Figure S4h). In those two
city samples the recruitment chains have often ended once
HIV positive participants were recruited. A graphical rep-
resentation of the recruitment networks (including HIV
and HCV serostatus) in each study city is displayed in the
(See Additional file 10: Figure S4a-b, Additional file 11:
Figure S4c-d, Additional file 8: Figure S4e-f, Additional file
9: Figure S4g-h).
In all cities we observed a decreased interest in par-
ticipation in the days following the monthly “social
benefit”-payment. We did not experience recruitment
challenges such as commercial exchange of coupons,
imposters or duplicate recruits.
Discussion
This paper presents first findings of the first large
bio-behavioural survey among PWID using RDS in
Germany. With a study sample of 2,077 participants, the
results of the study provide recent data on current HCV
and HIV prevalence, socio-demographical factors and
behaviours among PWID in Germany. Our results show
that HCV is endemic among the study populations (42.3–
75.0 %). This result is similar to estimations from available
regional surveys and reported data from several European
countries [47]. Viremic HCV infections among the partici-
pants were found to range between 23.1–54.0 %. In con-
trast to previous findings from sub-regional surveys in
Germany [28], HIV prevalence varied widely between the
city samples ranging from 0 % in Leipzig to 9.1 % in
Frankfurt. HIV prevalence of more than 5 % was found
in four of the city samples. These results are higher
compared to reported data on the HIV prevalence in
PWID in many other Western European countries, such
as the United Kingdom, Denmark, Norway, Austria, or
Luxemburg, but still lower than in countries like Italy,
Portugal and France [48].
HIV and HCV seroprevalences were both found to be
geographically heterogeneous. While Leipzig was the city
sample with the lowest prevalences, participants in
Essen, Hanover and Frankfurt had high levels of HIV
and HCV infections. The differences between the loca-
tions might be due to several factors. We identified three
characteristics that might be associated with the differ-
ent levels of HIV and HCV prevalence across the cities:
First, age (closely linked with duration of injecting),
second, drug use patterns in each city and third, the
history of intravenous drug use and the HIV epidemic in
the region. In Essen, Hanover and Frankfurt (all city
samples with high levels of HIV and HCV infections)
study participants were generally older and duration of
injecting was longer than in Leipzig. This is consistent
with the trend of aging injecting drug user-populations
in Germany and Europe at large. The longer a person
has injected drugs, the more likely it is that this person
will have been exposed to blood-borne pathogens [5].
The sample of Cologne seems to be an exception with
an unexpected low HIV seroprevalence. However, as
described, in this city HIV-positive persons were re-
cruited only in a late stage of the recruitment process
shortly before the end of the study. We therefore
might underestimate the true HIV prevalence in this
city sample. Further research will be needed to ex-
plain this discrepancy.
The different HCV and HIV prevalence might also be
associated with the varying use of cocaine, crack and
methamphetamines in the cities. Cocaine was found to
be most common in Hamburg, Hanover and Essen
while crack was mostly used in Frankfurt, Hanover
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and Hamburg, all of which are cities with a high HIV and
HCV prevalence. Cocaine and crack have a shorter
biological half-life and need to be consumed more
frequently than other substances in order to maintain their
effect [49, 50]. PWID who use cocaine or crack may conse-
quently be more exposed to unsafe use than PWID who
use substances requiring less injections. Methamphetamine
was found to be most common in Leipzig. This confirms
an increasing trend of methamphetamine use in border re-
gions to Czech Republic like Saxony reported in the last
years [51–54]. Methamphetamine has a longer biological
half-life than heroin and may thus be less frequently
injected [55]. Furthermore, the distinct demographic char-
acteristics and consumption patterns in Leipzig might be
related to the division of Germany to East and West until
1990. A drug scene in the former East probably developed
only after the German re-unification in 1990. While HIV
incidence among PWID in West Germany peaked in the
mid-1980s, in the Eastern part of Germany the spread of
HIV was delayed in time [56]. The delayed epidemic of
intravenous drug use and associated blood-borne in-
fections in East Germany are reflected in our results.
According to the national HIV case-reporting system HIV
is present among PWID in Leipzig with two reported
cases in 2012 and three in 2015 [57]. This indicates an
ongoing HIV transmission, albeit on a low level [58]. In
our sample of Leipzig, we found the highest proportion of
new injectors and the highest proportion of participants
testing HCV RNA-positive in the stage of seroconversion,
likewise indicating ongoing transmissions. This result is
consistent with evidence that HCV incidence is rapidly
increasing among new injectors [7, 59].
Injecting and sexual risk behaviours
Risk behaviours (30-day prevalence) like using unsterile
paraphernalia (spoons, filters or water), sharing of unster-
ile n/s and practicing unsafe sex, also with non-IDU (12-
month prevalence), was reported in all city samples. In the
last two decades, harm reduction interventions like NSP
in high income countries, including Germany have led to
a remarkable decline in the re-use of unsterile n/s and in
HIV incidence among PWID [60–63]. From our findings
we must conclude that either the access to clean n/s is still
insufficient and/or that there are still knowledge gaps
around transmission and preventive behaviour of HIV and
HCV. In other studies, sharing of other paraphernalia still
persists at higher levels than sharing n/s among PWID
[64–66]. This was also reflected in our study: sharing
other paraphernalia appeared much more common than
sharing n/s which was most prevalent in the sample of
Frankfurt. In this particular case, the high discrepancy
might be related to the high number of crack users. Crack
is generally linked to a high consumption frequency, and
thus with an increased use of paraphernalia.
Several studies have demonstrated that HCV is more
infectious than HIV and a prolonged survival of HCV in
syringes and non-syringe injecting paraphernalia has
been shown [67, 68]. Not surprisingly and in line with
data from other Western European countries, HCV
infections therefore appeared to be more prevalent
within the study population than HIV [26].
High proportions of the participants reported that
their last sexual intercourse was unprotected. The last
sexual partner was frequently reported to be an injecting
drug user as well, but it was also not uncommon that the
sexual partner was a non-PWID. The reported sexual
behaviours thus demonstrate the potential risk of spread-
ing HIV through the sexual route. While other studies
have demonstrated the higher risk of non-PWID to
acquire HIV [69], in Germany, little is known about HIV
prevalence among the non-injecting sexual partners of
PWID and their potential risk of being a bridge popula-
tion between PWID and the general population. Therefore
further research is needed to better understand the HIV/
HCV prevention needs of sex partners of PWID who do
not inject drugs themselves.
The study found high rates of incarceration (at least
once in lifetime) among the study participants. Unsafe
drug use and tattooing/piercing in prison were reported
as common practices while in prison, thus constituting
important risk factors for the transmission of HIV and
HCV. Several studies have shown that not only drug use
but also HIV and HCV infections among people in
prison are of major concerns in Germany [70, 71]. The
provision of harm reduction services in the criminal
justice system seems to be insufficient, only one of 186
prisons in Germany offers NSP [72], and there are large
variations regarding the availability of OST in prisons
across the federal states [70, 73].
Our study shows that HCV and HIV testing rates
(12-month prevalence) remained moderate to high in
the study populations in comparison to other risk groups,
like men who have sex with men [74]. Especially the large
variation in the HCV testing rates across the study cities
may be linked to the variation of participants who re-
ported undergoing OST at the time of participating, but
this needs further investigation.
An important limitation of our study is that it only
provides a snap shot of the HIV and HCV epidemi-
ology among PWID in Germany but it does not allow
determination of cause-effect relationships. Further-
more, the selection of our study cities was based on
the availability of low-threshold drug services in the
cities willing and able to participate in the study. Since
national representative data on PWID in Germany are
not available, we cannot claim that the PWID re-
cruited in the chosen cities are representative for all
PWID in Germany.
Wenz et al. BMC Public Health  (2016) 16:927 Page 10 of 14
Respondent driven sampling
The application of RDS as a method to recruit PWID
was successful. We reached the targeted sample size
within the set time frames in all cities except in one, and
our primary and secondary incentives seemed appropri-
ate to motivate PWID to enroll in the study. This is in
line with other studies, showing that RDS is an effective
recruitment method among PWID [35, 75].
The choice of low-threshold drug services as study
venues probably increased the willingness of participation.
We observed long recruitment chains in seven of the eight
city samples, indicating that PWID are well connected via
social networks or through making use of the low-
threshold drug services. However, we cannot exclude
selection bias of the city samples due to oversampling of
persons as initial seeds as well as participants who showed
communicative competence, well understood the study
flow and the background of the study, and who were will-
ing to recruit others for participation. Persons with a
lower bonding to the drug scene or less communicative
skills might be underrepresented in the samples.
Due to the extensive questionnaire, we refrained from
asking the participants how many PWID rejected their
coupons during the recruitment process. Reasons for
rejecting and the number of PWID who refused are
therefore unknown. It is possible that unknown barriers
restricted participation and potentially created a bias.
Yet we assume that our samples mostly attained adequate
socio-metric depth, given that equilibrium was reached
for four out of five key variables while reaching up to 20
waves in our samples. However, not all city samples allow
robust weighting of results, as equilibrium was not
reached in all and the length of the recruitment chains
was too short in the city of Leipzig. In this city we re-
cruited PWID in two low-threshold drug services with
alternating study operating hours. This seems to have
confused some study participants and it is possible that
further potential participants were lost due to this fact.
Equilibrium could be reached in the other seven samples,
showing that bias introduced by the initial non-randomly
selected seeds could be eliminated in these samples.
Despite the popularity and the widely applied method-
ology of RDS as a sampling method it is not known
whether RDS can generate unbiased estimates. The as-
sessment of RDS as a method of data analysis (RDS in-
ference) is challenging as it often fails to produce precise
results due to the unknown underlying truth [76]. Also,
the key variable used to generate the RDS-generated
estimates is the reported network size of the participant
which may not have been consistently addressed by all
interviewers or not consistently understood by all partic-
ipants, leading to a large range and thereby further
uncertainty about the validity of the RDS estimates. In
2012 McCreesh et al. have performed a RDS study with
known characteristics in order to assess the precision
and relevance of RDS inference and found that RDS
failed to reduce bias when it occurred, and even tended
to overestimate biased adjusted results [77]. In case
biases occur in practice the method is not designed to
correct for the sources of biases. RDS-generated esti-
mates should therefore be interpreted with caution and
are only shown in the Additional file 1: Table S1.
Conclusions
To best of our knowledge this study is the first bio-
behavioural study using RDS in Germany successfully
recruiting members of the target population. This paper
presents basic descriptive results for key variables in all
of the eight study cities. HCV was found to be hyperen-
demic within the study population. HIV and HCV sero-
prevalence were geographically heterogeneous, although
unsafe use behaviour, such as sharing n/s and other
paraphernalia, unsafe sex, and incarceration was com-
mon among all city samples.
Based on our findings, efforts to reduce sharing of
non-syringe paraphernalia and to further reduce the use
of unsterile n/s are urgently needed in Germany. We
furthermore recommend to scale up and increase the
access to multilevel and combined HCV and HIV pre-
vention, including antiviral treatment, OST and volun-
tary counselling and testing (VCT) for PWID. Our study
suggests that there might be opportunities to better inte-
grate VCT services in low-threshold drug services, as
they were used by up to 90 % of the participants (30-day
prevalence). Based on the large regional differences
observed in our study, we suggest developing context
specific interventions. Harm reduction programmes
should particularly consider new injectors. Internation-
ally, there is consensus in the scientific discourse about
the need to provide prevention, treatment and care in-
terventions for all, people living in freedom as well as
for prisoners [78].
Further in-depth analyses of the collected data will
reveal possible associations between infections and be-
havioural factors and other characteristics, to derive
concrete recommendations for current prevention strat-
egies for HCV and HIV among PWID.
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